

Polsinelli Assists API Innovation Center in Obtaining First DPA Title III Award to Bolster U.S. Pharmaceutical Independence

(Sept. 26, 2024) Am Law 100 firm Polsinelli recently advised client API Innovation Center (APIIC) on its successful application to obtain funding by the Administration for Strategic Preparedness and Response's (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC) to lead the development and domestic production of three critical active pharmaceutical ingredients (APIs) used in the treatment of asthma, diabetes and anxiety disorders. APIIC is a 501(c)(3) nonprofit public benefit organization headquartered in St. Louis, dedicated to driving health security and economic growth for the nation and its citizens through U.S.-based production of critical medicines. This is the Biden-Harris Administration's first award under the Defense Production Act Title III to onshore manufacturing of active pharmaceutical ingredients for essential medicines.

IBMSC will provide \$14 million in funding and APIIC will invest an additional \$2.4 million into the development of these critical APIs. This funding marks a significant step forward in securing the U.S. pharmaceutical supply chain and addressing national health security risks.

More information on the news can be found [here](#).

Shareholders Arindam Kar and James W. Kim advised the client in this matter along with Associates Cate Baskin and Elizabeth Snyder.

About Polsinelli

Polsinelli is an Am Law 100 firm with more than 1,000 attorneys in over 20 offices nationwide. Recognized as one of the top firms for excellent client service and client relationships, Polsinelli is committed to meeting our clients' expectations of what a law firm should be. Our attorneys provide value through practical legal counsel infused with business insight, offering comprehensive corporate, transactional, litigation and regulatory services with a focus on health care, real estate, finance, technology, private equity and life sciences. Polsinelli PC, Polsinelli LLP in California, Polsinelli PC (Inc) in Florida.

About the API Innovation Center:

The API Innovation Center (APIIC) is a 501(c)(3) nonprofit public benefit organization headquartered in St. Louis, Missouri, dedicated to driving health security and economic growth for the nation and its citizens through U.S.-based production of critical medicines. By investing in and collaborating along the supply chain, APIIC's model contracts with leading U.S.-based specialists within their pharmaceutical ecosystem to develop and manufacture high-quality domestically produced Active Pharmaceutical Ingredients. APIIC is also committed to expanding access to critical medications through strategic partnerships to commercialize market-competitive supplies of finished drug products and build resiliency in the supply chain. Their mission is to ensure every hospital, pharmacy, and patient has access to domestically produced critical medication to fortify national health security. APIIC is supported by the

state of Missouri through the Advanced Manufacturing Resiliency Grant awarded by the Missouri Technology Corporation. To learn more, visit: apicenter.org.

<<Reference Number>>

98699171.4